Use of MIN-102 for the treatment of children with cerebral ALD

Project Information

MIN4ALD

Grant agreement ID: 822968

DOI

10.3030/822968

Project closed

EC signature date 5 September 2018

Start date 1 October 2018

End date 30 June 2022

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 5 216 567,51

EU contribution

€ 3 106 250,00

Coordinated by

MINORYX THERAPEUTICS S.L.
Spain

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (1)

The brain penetrant PPARγ agonist leriglitazone restores multiple altered pathways in models of X-linked adrenoleukodystrophy

Author(s): Laura Rodríguez-Pascau, Anna Vilalta, Marc Cerrada, Estefania Traver, Sonja Forss-Petter, Isabelle Weinhofer, Jan Bauer, Stephan Kemp, Guillem Pina, Sílvia Pascual, Uwe Meya, Patricia L. Musolino, Johannes Berger, Marc Martinell, Pilar Pizcueta
Published in: Science Translational Medicine, Issue 13/596, 2021, ISSN 1946-6234
Publisher: American Association for the Advancement of Science
DOI: 10.1126/scitranslmed.abc0555

Intellectual Property Rights

Patent (6)

5-[[4-[2-[5-(1-HYDROXYETHYL)PYRIDIN-2-YL]ETHOXY]PHENYL]METHYL]-1,3-THIAZOLIDINE- 2,4-DIONE FOR TREATING NONALCOHOLIC FATTY LIVER DISEASE

Application/Publication number: 17 817175
Date: 2017-12-01
Applicant(s): MINORYX THERAPEUTICS S.L.

USE OF 5-[[4-[2-[5-ACETYLPYRIDIN-2-YL]ETHOXY]BENZYL]-1,3-THIAZOLIDINE-2,4-DIONE AND ITS SALTS

Application/Publication number: 20 19054744
Date: 2019-06-06
Applicant(s): MINORYX THERAPEUTICS S.L.

2,4-THIAZOLIDINEDIONE DERIVATIVES IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

Application/Publication number: 15 713499
Date: 2015-04-01
Applicant(s): MINORYX THERAPEUTICS S.L.

METHOD OF ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF 5-[[4-[2-[5-(1-HYDROXYETHYL)PYRIDIN-2-YL]ETHOXY]PHENYL]METHYL]-1,3-THIAZOLIDINE-2,4-DIONE

Application/Publication number: 20 19054743
Date: 2019-06-06
Applicant(s): MINORYX THERAPEUTICS S.L.

5-[[4-[2-[5-(1-HYDROXYETHYL)PYRIDIN-2-YL]ETHOXY]PHENYL]METHYL]-1,3-THIAZOLIDINE-2,4-DIONE AND ITS SALTS FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISEASES

Application/Publication number: 20 19054696
Date: 2019-06-06
Applicant(s): MINORYX THERAPEUTICS S.L.

PROCESS FOR PREPARING 5-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]METHYL]-2,4-THIAZOLIDINEDIONE AND SALTS THEREOF

Application/Publication number: 17 829042
Date: 2017-12-22
Applicant(s): MINORYX THERAPEUTICS S.L.